A weekly summary of insider trading highlighting a few notable buying and selling by investors, directors and executives. The ...

Ronald E. Blaylock, a director at Pfizer Inc. (NYSE:PFE), purchased 19,457 shares of the company's common stock. The ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.

Animal health company Zoetis (NYSE:ZTS) will be reporting results tomorrow before market open. Here’s what to look for.

Jefferies analyst Akash Tewari increased the price target for Pfizer (NYSE:PFE) shares from $33.00 to $34.00, while ...

RBC Capital Markets reiterated their positive stance on Alnylam Pharmaceuticals (NASDAQ:ALNY), maintaining an Outperform rating and a price target of $300.00. According to InvestingPro data, analyst ...

H.C. Wainwright research firm maintained a positive outlook on ORIC Pharmaceuticals (NASDAQ:ORIC), reiterating a Buy rating and a $21.00 price target for the company's stock. Currently trading at $11.

OpenAI’s Sam Altman isn’t keen on potential Musk takeover, BP promises big reset as earnings hit 4-year low, and more news to ...

JMP Securities reiterated a Market Outperform rating on Enanta Pharmaceuticals (NASDAQ:ENTA) shares with a consistent price target of $21.00. The firm's analysis highlighted the company's solid ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...